US Stock MarketDetailed Quotes

TLSA Tiziana Life Sciences

Watchlist

1.3876
-0.0124-0.89%

Trading Aug 8 13:31 ET

143.04MMarket Cap-8162P/E (TTM)

Tiziana Life Sciences Stock Forum

Green Dragon 2024

Jul 25 09:29

Update

$Tiziana Life Sciences (TLSA.US)$
expected move and now they should announce soon orphan drug status, and then later the results and then later they will be bought out… comment from biotech guy

Tiggerpepper

Jul 24 08:24

🚀

$Tiziana Life Sciences (TLSA.US)$ make my day TLSA into a salary.

Trytosaveabit

Jul 24 06:16

Posted May 13 this was submitted!

$Tiziana Life Sciences (TLSA.US)$ Only about 72 days from submission to approval! Not to bad FDA! Hehehe

Trytosaveabit

Jul 24 06:11

C’mon now. You can do better than that!

$Tiziana Life Sciences (TLSA.US)$ Hehehe🤫

Trytosaveabit

Jul 24 06:04

News

$Tiziana Life Sciences (TLSA.US)$ Reuters· 3 mins ago
Tiziana Life Sciences Ltd - FDA Grants Fast Track for Intranasal Foralumab

Trytosaveabit

Jun 11 07:02

Update

$Tiziana Life Sciences (TLSA.US)$ Reuters· 1 min ago
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Trytosaveabit

Jun 6 08:07

Update

$Tiziana Life Sciences (TLSA.US)$ Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab

InvTrdBTC

Jun 4 22:11

AvidTrader recommends

My Money Says This $1 Penny Stock Could Reclaim Its Previous $12 High
Check out the video above.
$Tiziana Life Sciences (TLSA.US)$

Jaguar8

Jun 4 08:05

NEWS

$Tiziana Life Sciences (TLSA.US)$
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
Tiziana Life Sciences (Nasdaq: TLSA), a biotechnology company, has applied for a grant from the ALS Association to fund a clinical trial for intranasal foralumab, an anti-CD3 monoclonal antibody. The grant is part of the Hoffman ALS Clinical Trial Awards Program. The trial aims to evaluate the safety, dosing, and biomarkers of foralumab in ALS pat...